SupportLoginSign Up
Featured FeedJournalsCollectionsKeywordsSaved Papers
Add like
Add dislike
Add to saved papers

Treating MCL with CAR T Cells.

(no author information available yet)
Cancer Discovery 2020 June
KTE-X19, an investigational chimeric antigen receptor T-cell therapy, has shown promising efficacy in patients with relapsed/refractory mantle cell lymphoma. Based on data from the ZUMA-2 trial, it is now under the FDA's priority review and could soon be a new standard of care for this rare hematologic malignancy.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.
Show additional links to paperHide additional links to paper
PubMed

Add to Saved Papers

Get 1-tap access

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Do Not Sell My Personal InformationManage Cookie Preferences

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app